FDA
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
-
-
-
-
-
-
-
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
-
-
-
-
-
-
-
Zymeworks appoints Brian Cherry to board, promotes executives
-
-
-
-
-
-
-
Zymeworks shifts strategy to focus on royalty-driven growth model
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)
-
-
-
-
-
-
-
Zymeworks names Dr. Schayowitz acting chief development officer
-
326,363 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

